<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910386</url>
  </required_header>
  <id_info>
    <org_study_id>KN035-US-002</org_study_id>
    <nct_id>NCT04910386</nct_id>
  </id_info>
  <brief_title>Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers</brief_title>
  <official_title>A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3D Medicines (Sichuan) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3D Medicines</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety&#xD;
      of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus&#xD;
      Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary&#xD;
      Tract Cancers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Observed by 12 weeks</time_frame>
    <description>To evaluate the progression-free survival (PFS) of envafolimab in combination with gemcitabine plus cisplatin (GemCis) versus first-line treatment of GemCis in patients with advanced biliary tract cancers (BTC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Observed by 12 weeks after progressive disease or end of treatment</time_frame>
    <description>To evaluate the overall survival (OS) of envafolimab in combination with GemCis versus GemCis in patients with advanced BTC;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>Observed by 12 weeks</time_frame>
    <description>To evaluate the objective response rate (assessed by the investigator per RECIST 1.1 criteria) of envafolimab in combination with GemCis versus GemCis in patients with advanced BTC;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Observed by 12 weeks</time_frame>
    <description>To evaluate the duration of response (assessed by the investigator per RECIST 1.1 criteria) of envafolimab in combination with GemCis versus GemCis in patients with advanced BTC;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Observed by 12 weeks</time_frame>
    <description>To evaluate the disease control rate (assessed by the investigator per RECIST 1.1 criteria) of envafolimab in combination with GemCis versus GemCis in patients with advanced BTC;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Biliary Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>Envafolimb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Envafolimab plus Gemcitabine&amp;Cisplatin Envafolimab: 300 mg on Day 1 of each cycle, subcutaneous injection. Every 21 days is a treatment cycle.&#xD;
Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.&#xD;
Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine&amp;Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine (GEM): 1000 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.&#xD;
Cisplatin (CIS): 25 mg/m2 body surface area (BSA) administered on Days 1 and 8 of each cycle. Every 21 days is a treatment cycle with a maximum of 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Envafolimab plus Gemcitabine&amp;Cisplatin</intervention_name>
    <description>Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision</description>
    <arm_group_label>Envafolimb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine&amp;Cisplatin</intervention_name>
    <description>The standard of care for the patients with unresectable/metastatic biliary tract cancer</description>
    <arm_group_label>Gemcitabine&amp;Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be ≥ 18 years of age;&#xD;
&#xD;
          2. Subjects must have a histopathological or cytological diagnosis of locally advanced or&#xD;
             metastatic gallbladder cancer (GBC) or cholangiocarcinoma (CCA);&#xD;
&#xD;
          3. Subjects who have not received prior systemic therapy for advanced disease or who have&#xD;
             received adjuvant or neoadjuvant chemotherapy in one regimen and relapsed &gt; 6 months&#xD;
             after the end of chemotherapy can be enrolled;&#xD;
&#xD;
          4. Child-Pugh liver function rating: class A (5-6 points) and better class B (7 points)&#xD;
             (see Appendix 3);&#xD;
&#xD;
          5. ECOG PS score 0 or 1 (see Appendix 1);&#xD;
&#xD;
          6. Expected survival ≥ 12 weeks;&#xD;
&#xD;
          7. Subjects with at least one measurable lesion (RECIST 1.1 criteria, see Appendix 2);&#xD;
&#xD;
          8. Subject must have adequate major organ and bone marrow functions (no blood transfusion&#xD;
             and no use of hematopoietic growth factor within 14 days before the first dose of&#xD;
             study treatment):&#xD;
&#xD;
        1) Hematology: neutrophils ≥ 1.5 × 109/L, platelets ≥ 100 × 109/L, and hemoglobin ≥ 90 g/L;&#xD;
        2) International normalized ratio (INR) ≤ 1.5 × upper limit of normal (ULN) and activated&#xD;
        partial thromboplastin time (APTT) ≤ 1.5 × ULN; 3) Liver function: serum total bilirubin ≤&#xD;
        1.5 × ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels &gt;1.5 ULN;&#xD;
        Aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) ≤ 2.5 ×&#xD;
        ULN OR ≤ 5 × ULN for subjects with liver metastases; 4) Renal function: serum creatinine ≤&#xD;
        1.5 x ULN and creatinine clearance (CCr) &gt; 60 mL/min (assessed with Cockcroft-Gault&#xD;
        formula, see Appendix 6); 5) Normal cardiac function with left ventricular ejection&#xD;
        fraction (LVEF) ≥ 50% by two-dimensional echocardiography.&#xD;
&#xD;
        9. Subjects must fully understand the study, voluntarily participate, and sign the informed&#xD;
        consent form (ICF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has participated in another clinical trials of other investigational drugs or&#xD;
             investigational devices within 4 weeks prior to the first dose of investigational&#xD;
             product treatment (palliative radiotherapy for bone metastases completed at least 2&#xD;
             weeks prior to investigational product treatment is allowed);&#xD;
&#xD;
          2. The investigator assesses liver metastases as 50% or more of the total liver volume;&#xD;
&#xD;
          3. Has ascites requiring drainage or treatment with diuretics, or pleural or pericardial&#xD;
             effusion requiring drainage and/or associated with symptoms of tachypnea within 4&#xD;
             weeks prior to the first dose of investigational product treatment;&#xD;
&#xD;
          4. Has biliary obstruction with clinical intervention that has not resolved or requires&#xD;
             anti-infective therapy as judged by the investigator 14 days prior to the first dose&#xD;
             of investigational product treatment;&#xD;
&#xD;
          5. Has prior liver transplantation;&#xD;
&#xD;
          6. Has known active brain metastases or spinal cord compression; subjects with previously&#xD;
             treated brain metastases may be enrolled if their clinical condition is stable and&#xD;
             radiographic evidence shows no disease progression within 4 weeks prior to the first&#xD;
             dose of investigational product treatment, and corticosteroid therapy is not required&#xD;
             within 4 weeks prior to the first dose of investigational product treatment;&#xD;
&#xD;
          7. Has a known additional malignant tumor in the past 5 years (except for skin basal cell&#xD;
             or squamous cell carcinoma, or cervical, breast and other carcinoma in situ after&#xD;
             radical surgery);&#xD;
&#xD;
          8. Has received major surgical procedures (except biopsy) or incomplete healing of&#xD;
             surgical wound within 4 weeks prior to the first dose of investigational product&#xD;
             treatment;&#xD;
&#xD;
          9. Has any unresolved toxicity (CTCAE Grade ≥ 2) from prior anti-tumor therapy, except&#xD;
             for alopecia or Grade 2 peripheral neuropathy or other laboratory abnormalities that&#xD;
             are not clinically significant as assessed by the investigator;&#xD;
&#xD;
         10. Has an active autoimmune disease or a documented history of autoimmune disease or&#xD;
             syndrome that requires systemic steroids or immunosuppressive agents. Subjects with&#xD;
             vitiligo or resolved childhood asthma/atopy would be exception to this rule. Subjects&#xD;
             who require intermittent use of bronchodilators or local steroid injections would not&#xD;
             be excluded from the study. Subjects with hypothyroidism that is stable on hormone&#xD;
             replacement will not be excluded from the study;&#xD;
&#xD;
         11. Has known history of HIV, or active bacterial or fungal infection requiring systemic&#xD;
             treatment within 14 days prior to the first dose of investigational product treatment;&#xD;
&#xD;
         12. Has history of interstitial lung disease, drug-induced interstitial lung disease,&#xD;
             radiation pneumonitis, symptomatic interstitial lung disease or presence of active&#xD;
             pneumonitis on chest CT scan within 4 weeks before the first dose of investigational&#xD;
             product treatment;&#xD;
&#xD;
         13. Has active hepatitis B (HBsAg positive and HBV-DNA ≥ 104 copies/mL) or hepatitis C&#xD;
             (HCV antibody positive and HCV-RNA quantitative test results greater than the lower&#xD;
             limit of detection);&#xD;
&#xD;
         14. Has a history or current evidence of clinically significant cardiovascular diseases,&#xD;
             including but not limited to acute myocardial infarction, severe/unstable angina,&#xD;
             acute ischemic/hemorrhagic stroke, congestive heart failure (≥ New York Heart&#xD;
             Association Class II, see Appendix 4) within 6 months prior to enrollment; arrhythmias&#xD;
             requiring treatment with other antiarrhythmic drugs in addition to β-blockers or&#xD;
             digoxin; repeat QTcF interval &gt; 450 milliseconds (ms) on ECG (see Appendix 5);&#xD;
             hypertension not well controlled with antihypertensive drug therapy (systolic blood&#xD;
             pressure &gt; 150 mmHg, diastolic blood pressure &gt; 100 mmHg);&#xD;
&#xD;
         15. Be receiving therapeutic doses of warfarin (low-dose warfarin ≤ 2 mg/day is allowed);&#xD;
             or receiving antiplatelet anticoagulant therapy (aspirin doses ≤ 300 mg/day and&#xD;
             clopidogrel doses ≤ 75 mg/day are allowed);&#xD;
&#xD;
         16. Has received immunosuppressive drugs within 4 weeks prior to the first dose of&#xD;
             investigational product treatment, excluding topical corticosteroids or systemic&#xD;
             prednisone ≤ 10 mg/day or equivalent doses of other corticosteroids;&#xD;
&#xD;
         17. Has received live vaccines within 4 weeks before the first dose of investigational&#xD;
             product treatment or plan to receive it during the study;&#xD;
&#xD;
         18. Has history of severe allergic reactions to chimeric or human antibodies or fusion&#xD;
             proteins, or known allergies to biological products produced with Chinese hamster&#xD;
             ovary cells or any component of envafolimab; known or suspected allergy to the&#xD;
             chemotherapeutic drug gemcitabine/cisplatin and its components;&#xD;
&#xD;
         19. Be pregnant or breastfeeding;&#xD;
&#xD;
         20. Be childbearing potential but unwilling to accept effective contraceptive measures;&#xD;
&#xD;
         21. Any other disease, metabolic disorder or laboratory abnormalities, that the&#xD;
             investigator considers that the subject is not suitable for the investigational&#xD;
             product treatment, or will affect the interpretation of the study results, or put the&#xD;
             subject at high risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

